estrogen-receptor-positive breast cancer

Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research led by Matthew J. Ellis, MD, PhD, from Washington University School of Medicine in St. Louis.

Decoding the DNA of patients with advanced breast cancer has allowed scientists to identify distinct cancer “signatures” that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.

​With more than $5 million in new grants from Susan G. Komen for the Cure, Washington University scientists at the Alvin J. Siteman Cancer Center are developing innovative treatments in the fight against breast cancer.

High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

In the single largest cancer genomics investigation reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients’ healthy cells. They uncovered incredible complexity in the cancer genomes, but also got a glimpse of new routes toward personalized medicine.